23 February 2009 /Side effects and trials
EMEA has reviewed two cases from Spain, where two girls experienced prolonged and severe seizures with loss of consciusness after they had been vaccinated with the cervical cancer vaccine Gardasil®.
20 February 2009 /Side effects and trials
The European Medicines Agency (EMEA) recommends the European Commission to suspend the marketing authorisation of Raptiva®
The Committee for Medicinal Products for Human Use (CHMP) under EMEA has concluded that the benefit of the medicinal product Raptiva® (efalizumab) for patients with moderate plaque psoriasis can no longer justify the risk of a number of serious adverse reactions, first and foremost progressive multifocal leukoencephalopathy (PML)
17 February 2009 /News - miscellaneous
On 14 January, the results of two scientific studies were published in the US journal Neurology. The studies examined the effect of so-called conjugated oestrogens on the brain in women above the age of 65.
16 February 2009 /Side effects and trials
The HPV vaccine Gardasil® provides protection for cervical cancer. The vaccine has been on the Danish market since 2006. As of 1 January 2009, the vaccine is included in the Danish childhood immunisation programme as an offer for all 12-year-old girls.
16 February 2009 /Retail and online sale
Today, the Danish Medicines Agency launches a campaing against dangerous weight-loss products (containing e.g. ephedrine). The reason is that these products represent a major health risk to consumers and have already resulted in serious adverse reactions.
16 February 2009 /News - miscellaneous
European cooperation on the replacement of animal testing with the PCR technique in the testing of veterinary vaccines
On 27-28 Ocotber 2008, the European Directorate for the Quality of Medicines & Healthcare (EDQM) held a meeting in Strasbourg on the use of the PCR (Polymerase Chain Reaction) technique in the testing of veterinary vaccines.
03 February 2009 /Side effects and trials
Dotarem® is a gadolinium-containing contrast agent used in connection with MRI scanning. Gadolinium-containing contrast agents must be used with extreme care when scanning patients with renal impairment because these patients excrete the contrast agent significantly slower than patients with normal renal function.
02 February 2009 /Prices and reimbursement
Consultation responses on the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09
The Danish Medicines Agency's assessment of the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09 for the treatment of cardiovascular diseases has been submitted for consultation with 11 December 2008 as the consultation deadline.
16 January 2009 /Side effects and trials
In February 2007, the Danish Medicines Agency changed its recommendations concerning the use of Omniscan for kidney patients due to a strong suspicion that the contrast medium may cause the serious adverse reaction: Nephrogenic Systemic Fibrosis
15 January 2009 /About us
As of 1 January 2009, the Danish Medicines Agency implements an organisational change which entails that the Pharmacoeconomic Division will be closed down.
13 January 2009 /News - miscellaneous
The Danish movie "Den Du Frygter" (The One You Fear), which premiered on 19 December, focuses on trials of medicine. The main character in the film participates in a trial that is cancelled due to dangerous side effects.
13 January 2009 /Product information
The many cases of scabies all over Denmark has led to a lack of the medicine, Nix, which is authorised for scabies treatment in Denmark. In cooperation with the Assocation of Danish Pharmacies and the Danish Medicines Agency, the importer has come up with a solution which will ensure relief this week.